


From Medical Robotic Platforms Dedicated to Surgery to the Next Medical Robotic Platforms Dedicated to Cancer Therapy (Medical Nanorobotics)





## Motivation

- For 2013 in US alone: an estimated 1,660,290 new cancer cases.
- This results to approximately 580,350 deaths almost 1,600 people per day or 1 every 54 seconds.
- With an estimated today's world population of 7.119 billion individuals with US population representing only 4.45%, one can easily realize the importance of finding new or improved treatment modalities.

# **Robotic Approach to Tumor Targeting**

- FACT: More than 80% of cancers are localized in the form of a solid tumor
  - So why going everywhere (systemic circulation) instead of delivering the therapeutics using the most direct physiological routes (non-systemic delivery)


#### • Direct targeting (new concept)


 Pharmaceutical carriers or agents (nanobots) being navigated directly from the injection site to the targeted area

5

- Avoid or at least reduce systemic circulation
- Can be combined with passive or active targeting


# <section-header><section-header><text><text><text>





How to resolve that – An engineering approach: Providing a therapeutic agent having the following general robotic capabilities:


- Navigation
  - Non-systemic circulation
- Actuation (propelling thrust force)
  - Deeper in the tumor volume passed the diffusion limit
- Sensory capability
  - To target non-visible hypoxic zones in tumors



#### **MC-1 Magnetotactic Bacterium**


 Since an artificial implementation is far beyond technological feasibility, a potential strategy was to identify a microorganism that has all these specifications and to harness it to act as a "nanorobot" for drug delivery

applications





Gram-negative procaryotes

Pettaquamscutt Estuary in Rhode Island, USA




#### **Harnessing What Nature Already Provides**






# **Taxis-based Directional Control**



Reference: S. Martel, "Bacterial Microsystems and Microrobots," Biomed. Microdevices, 2013








# MC-1 Strain Magnetococcus Marinus Natural Migration Behavior

- Contains a chain of magnetic iron-oxide (Fe<sub>3</sub>O<sub>4</sub>) nanocrystals enclosed in membranes known as magnetosomes acting like a nano-compass needle.
- Downward migration along geomagnetic field lines in conjunction with aerotaxis to efficiently migrate to and maintain position at their preferred low oxygen concentrations.
- Such magnetically-assisted aerotaxis known as magneto-aerotaxis results in the formation of microaerophilic bands of MC-1 cells at O<sub>2</sub> concentrations equivalent to the ones observed in the hypoxic regions of solid tumors.



19

Nanorobotique () Nanorobotiçs Polytechnique Montreal












POLYTECHNIQUE MONTRÉAL

### **Magnetic Pole**







$$B_{Z} = \frac{\mu_{0}I}{2\pi a \sqrt{(1+\alpha)^{2} + \beta^{2}}} \left[ E(k) \frac{1-\alpha^{2}-\beta^{2}}{(1+\alpha)^{2}+\beta^{2}-4\alpha} + K(k) \right] \dots$$




#### Nanorobolique ۲ • ÉCOLE Nanorobotics MONTRÉA




#### **Oxygen Sensors – Microaerophilic Behavior** (Objective: Autonomous Targeting of Tumor Hypoxic Zones)








#### Attachment of activated drug-loaded liposomes (or polymeric containers) to functional groups of MC-1 cells using carbodiimide chemistry




Taherkhani S., Mohammadi M., Daoud J., Martel S., and Tabrizian M., Covalent binding of nanoliposomes to the surface of magnetotactic bacteria acting as self-propelled target delivery agents," *ACS Nano*, 2014 (DOI: 10.1021/nn5011304)

Nanorobotique () Nanorobotiçs Polytechnoue Nanorobotiçs Polytechnoue

#### **Targeting Hypoxic Regions in Tumors**







# Acknowledgements

- Several funding organisms are acknowledged for their support and vision by providing the resources required to pursue the development of these technologies. The main supporting organizations include Polytechnique Montréal, Univalor, Consortium Québécois sur la Découverte du Médicaments (CQDM), CMC Microsystems, ReSMIQ, GRSTB, Canada Research Chair (CRC) Program, Natural Sciences and Engineering Research Council of Canada (NSERC), Government of Québec, Canadian Funds for Innovation (CFI), National Institute of Health (NIH), and several other organisms that contributed financially to our partners and students.
- The active participation of many individuals besides the staff, the graduate students and the technicians is worth mentioning and the list of participants in such highly interdisciplinary projects to make it accessible clinically in the future is growing.
- In alphabetical order (current immediate collaborators in medical applications only):
- G. Batist Oncologist, McGill University
- N. Beauchemin Biochemist, McGill University
- G. Beaudoin Medical Physics and MRI sequencing, University of Montréal
- F. Cheriet Medical imaging, Polytechnique Montréal
- L. Gaboury Pathologist, University of Montréal
- S. Kadoury Medical image registration, Polytechnique Montréal
- M. Lafleur Chemist, University of Montréal
- M. Mohammadi Biologist, bacterial culture, Polytechnique Montréal
- D. Radzioch Immunologist, McGill University
- G. Soulez Interventional Radiologist, University of Montréal
- M. Tabrizian Biomaterials and Bio-interfaces, McGill University
- T. Vuong Radio-oncologist, McGill University

Nanorobotique Nanorobotics Sylvain Martel

NanoRobotics Laboratory Polytechnique Montreal, CANADA

Contact: sylvain.martel@polymtl.ca

